Bispecific antibodies targeting CD20xCD3 in immunotherapy for adult B-cell lymphoma: insights from the 65th American Society of Hematology 2023 annual meeting.
Expert Opin Biol Ther
; 24(5): 321-326, 2024 May.
Article
in En
| MEDLINE
| ID: mdl-38717336
ABSTRACT
INTRODUCTION:
At the 65th American Society of Hematology (ASH) 2023 Annual Meeting, the latest advancements in CD20×CD3 BsAbs for B-cell lymphoma (BCL) were highlighted, particularly in relapsed/refractory (R/R) follicular lymphoma (FL) and R/R diffuse large B-cell lymphoma (DLBCL). AREAS COVERED This summary highlights some of the major studies on CD20×CD3 BsAbs for BCL. EXPERT OPINION/COMMENTARY CD20×CD3 is the most widely studied BsAb, with promising results in patients with R/R DLBCL and R/R FL ≥ two prior lines of systemic therapy. Trials with the first line of B-cell lymphoma also revealed promising results. Hopefully, BsAb monotherapy or BsAb-containing regimens may become the standard therapy in patients with FL and DLBCL.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Lymphoma, Large B-Cell, Diffuse
/
CD3 Complex
/
Antibodies, Bispecific
/
Antigens, CD20
/
Immunotherapy
Limits:
Adult
/
Humans
Language:
En
Journal:
Expert Opin Biol Ther
/
Expert opin. biol. ther. (Online)
/
Expert opinion on biological therapy (Online)
Journal subject:
BIOLOGIA
/
TERAPEUTICA
Year:
2024
Document type:
Article
Affiliation country:
China
Country of publication:
Reino Unido